The Translational Medicine Group is a new program established with the goal of accelerating the advance of new therapeutics into clinical practice. The TMG works closely with the basic science teams in the CCIB to help identify targets for new therapies. Once new compounds with sufficient activity to test in vivo have been developed, the Translational Medicine Group co-develops the pre-clinical study plan needed to provide the rationale and safety package to gain regulatory approval to enter clinical trials.

The TMG then designs, organizes, and conducts first-in-human experimental studies to evaluate the safety and efficacy of these medicines. The source of new compounds for the TMG's work is not restricted to the CCIB's own therapeutics center, but will also include therapies originating from outside laboratories at Massachusetts General Hospital/Harvard and other academic centers, as well as from the biotech and pharmaceutical industries.